KBC Group’s Xeris Biopharma Holdings XERS Stock Holding History

KBC Group’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36K	Hold	4,573	–	–	﹤0.01%	1796
2026 Q1	$27K	Buy	+4,573	New	+$30.3K	﹤0.01%	1816

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

KBC Group's XERS Position: Q2 2026 in Review

KBC Group held its Xeris Biopharma Holdings (XERS) position steady in Q2 2026 at 4,573 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #1796.

KBC Group first reported a position in XERS in Q1 2026 and has held it in 2 quarters since. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

KBC Group held 4,573 shares of Xeris Biopharma Holdings worth $36K as of Q2 2026.
KBC Group left its Xeris Biopharma Holdings share count unchanged in Q2 2026.
Xeris Biopharma Holdings made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1796 holding.
KBC Group first reported a position in Xeris Biopharma Holdings in Q1 2026 and has held it in 2 quarters since.
241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.